Crinetics to be acquired by Vertex for $10.0B
Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share. Net product revenue for the quarter was $24.0 million.
View filing at SEC.gov →2 most recent filings and news items mentioning CRNX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/CRNX/news?limit=20"
Pull CRNX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayVertex Pharmaceuticals agreed to acquire Crinetics for $85 per share. Net product revenue for the quarter was $24.0 million.
View filing at SEC.gov →Exhibit 2.1 details a definitive agreement where Clark Merger Sub will merge with and into Crinetics, creating a combined entity. This transaction bolsters Vertex's endocrine franchise as it pursues commercialization for its latest obesity drug.
View filing at SEC.gov →